Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press4910.17650/2220-3478-2012-0-3-321-338REVIEWОБЗОРЫ ЛИТЕРАТУРЫRole of microsatellite instability in colon cancerРоль микросателлитной нестабильности при раке толстой кишкиFedyaninM. Yu.ФедянинМ. Ю.
Russian Federation
fedianinmu@mail.ruTryakinA. A.ТрякинА. А.
Russian Federation
TjulandinS. A.ТюляндинС. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина»РАМН, Москва280220121319252802201528022015Copyright ©; 2012, ABV-pressCopyright ©; 2012, АБВ-пресс2012ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/49

Coloncancer is among leading causes of cancer morbidity and mortality both inRussiaand worldwide. Development of molecular biology lead to decoding of carcinogenesis and tumor progression mechanisms. These processes require accumulation of genetic and epigenetic alterations in a tumor cell.Coloncancer carcinogenesis is characterized by mutations cumulation in genes controlling growth and differentiation of epithelial cells, which leads to their genetic instability. Microsatellite instability is a type of genetic instability characterized by deterioration of mismatch DNA repair. This leads to faster accumulation of mutations in DNA. Loss of mismatch repair mechanism can easily be diagnosed by length of DNA microsatellites. These alterations are termed microsatellite instability. They can be found both in hereditary and sporadic colon cancers. This review covers the questions of microsatellite instability, its prognostic and predictive value in colon cancer.

colon cancermicrosatellite instabilityLynch syndromeрак толстой кишкимикросателлитная нестабильностьсиндром Линча1. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006;Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006;281:30305-9.:30305-9.2. Liu B., Nikolaides N.C., Markowitz S. et al. Mismatch repair gene defectsLiu B., Nikolaides N.C., Markowitz S. et al. Mismatch repair gene defectsin sporadic colorectal cancers with microsatellite instability. Nat Genet 1995; 9(1):48-55.3. Wang J., Sun L., Myeroff L. et al. Demonstration that mutation of the type IIWang J., Sun L., Myeroff L. et al. Demonstration that mutation of the type IItransforming growth factor beta receptor inactivates its tumor suppressor activity inreplication error-positive colon carcinoma cells. J Biol Chem 1995;270:22044-9.4. Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. CancerRes 2002;62(9):2447-54.5. Zaanan A.,Meunier K., Sangar F. et al. Microsatellite instability in colorectalZaanan A.,Meunier K., Sangar F. et al. Microsatellite instability in colorectalcancer: from molecular oncogenic mechanisms to clinical implications. CellOncol 2011;34(3):155-76.6. Mirabelli-Primdahl L., Gryfe R., Kim H. et al. Beta-catenin mutations are specificMirabelli-Primdahl L., Gryfe R., Kim H. et al. Beta-catenin mutations are specificfor colorectal carcinomas with microsatellite instability but occur in endometrialcarcinomas irrespective of mutator pathway. Cancer Res 1999;59(14):3346-51.7. Miyaki M., Iijima T., Kimura J. et al. Frequent mutation of beta-catenin and APCMiyaki M., Iijima T., Kimura J. et al. Frequent mutation of beta-catenin and APCgenes in primary colorectal tumors from patients with hereditary nonpolyposiscolorectal cancer. Cancer Res 1999; 59(18):4506-9.8. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of theThibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of theproximal colon. Science 1993;260:816-9.9. Umar A., Boland C.R., Terdinam J.P. et al. Revised Bethesda Guidelines forUmar A., Boland C.R., Terdinam J.P. et al. Revised Bethesda Guidelines forhereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatelliteinstability. J Natl Cancer Inst 2004;96:261-8.10. Boland C.R., Thibodeau S.N., Hamilton S.R. et al. A National CancerBoland C.R., Thibodeau S.N., Hamilton S.R. et al. A National CancerInstitute workshop on microsatellite instability for cancer detection and familialpredisposition: development of international criteria for determination of microsatelliteinstability in colorectal cancer. Cancer Res 1998;58(22):5248-57.11. Tejpar S. The multidisciplinary management of gastrointestinal cancer. The useTejpar S. The multidisciplinary management of gastrointestinal cancer. The useof molecular markers in the diagnosis and treatment of colorectal cancer. Best PractRes Clin Gastroenterol 2007;21:1071-87.12. Benatti P., Gafа R., Barana D. et al. Microsatellite instability and colorectalBenatti P., Gafа R., Barana D. et al. Microsatellite instability and colorectalcancer prognosis. Clin Cancer Res 2005; 11:8332-40.13. Raut C., Pawlik T., Rodriguez-Bigas M.A. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 2004; 568:275-82.Raut C., Pawlik T., Rodriguez-Bigas M.A. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 2004; 568:275-82.14. Warusavitarne J., Schnitzler M. The role of chemotherapy in microsatellite unstableWarusavitarne J., Schnitzler M. The role of chemotherapy in microsatellite unstable(MSI-H) colorectal cancer. Int J Colorectal Dis 2007;22(7):739-48.15. Ogino S., Nosho K., Kirkner G.J. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.Ogino S., Nosho K., Kirkner G.J. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.16. Nagasaka T., Koi M., Kloor M. et al. Mutations in both KRAS and BRAF mayNagasaka T., Koi M., Kloor M. et al. Mutations in both KRAS and BRAF maycontribute to the methylator phenotype in colon cancer. Gastroenterology 2008; 134:1950-60.17. Rajagopalan H., Bardelli A., Lengauer C. et al. Tumorigenesis: RAF/RAS oncogenesRajagopalan H., Bardelli A., Lengauer C. et al. Tumorigenesis: RAF/RAS oncogenesand mismatchrepair status. Nature 2002; 418:934.18. Boland C.R. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 2005; 4:211-8.Boland C.R. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 2005; 4:211-8.19. Vasen H.F., Mцslein G., Alonso A. et al. Guidelines for the clinical management ofVasen H.F., Mцslein G., Alonso A. et al. Guidelines for the clinical management ofLynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44(6):353-62.20. Peltomдki P. Lynch syndrome genes. Fam Cancer 2005;4(3):227-32.Peltomдki P. Lynch syndrome genes. Fam Cancer 2005;4(3):227-32.21. Peltomдki P., Vasen H.F. Mutations predisposing to hereditary nonpolyposisPeltomдki P., Vasen H.F. Mutations predisposing to hereditary nonpolyposiscolorectal cancer: database and results of a collaborative study. The InternationalCollaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113(4):1146-58.22. Huang J., Kuismanen S.A., Liu T. et al. MSH6 and MSH3 are rarely involved inHuang J., Kuismanen S.A., Liu T. et al. MSH6 and MSH3 are rarely involved ingenetic predisposition to nonpolypotic colon cancer. Cancer Res 2001;61(4):1619-23.23. de Jong A.E., van Puijenbroek M., Hendriks Y. et al. Microsatellite instability,de Jong A.E., van Puijenbroek M., Hendriks Y. et al. Microsatellite instability,immunohistochemistry, and additional PMS2 staining in suspected hereditarynonpolyposis colorectal cancer. Clin Cancer Res 2004;10:972-80.24. Halvarsson B., Lindblom A., Rambech E. et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer 2006;5:353-8.Halvarsson B., Lindblom A., Rambech E. et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer 2006;5:353-8.25. Hendriks Y.M., Jagmohan-Changur S., van der Klift H.M. et al. HeterozygousHendriks Y.M., Jagmohan-Changur S., van der Klift H.M. et al. Heterozygousmutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 2006;130:312-22.26. Hienonen T., Laiho P., Salovaara R. et al. Little evidence for involvement of MLH3Hienonen T., Laiho P., Salovaara R. et al. Little evidence for involvement of MLH3in colorectal cancer predisposition. Int J Cancer 2003;106:292-6.27. Llor X., Pons E., Xicola R.M. et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005;11:7304-10.Llor X., Pons E., Xicola R.M. et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005;11:7304-10.28. Gazzoli I., Loda M., Garber J. et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosityGazzoli I., Loda M., Garber J. et al. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosityof the unmethylated allele in the resulting microsatellite instability-high tumor. CancerRes 2002;62:3925-8.29. Ligtenberg M.J., Kuiper R.P., Chan T.L. et al. Heritable somatic methylation andLigtenberg M.J., Kuiper R.P., Chan T.L. et al. Heritable somatic methylation andinactivation of MSH2 in families with Lynch syndrome due to deletion of the 3 exons ofTACSTD1. Nat Genet 2009;41(1):112-7.30. Watson P., Vasen H.F., Mecklin J.P. et al. The risk of extra-colonic, extra-endometrialWatson P., Vasen H.F., Mecklin J.P. et al. The risk of extra-colonic, extra-endometrialcancer in the Lynch syndrome. Int J Cancer 2008;123:444-9.31. Vasen H.F., Mecklin J.P., Khan P.M. et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon RectumVasen H.F., Mecklin J.P., Khan P.M. et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum1991;34(5):424-5.;34(5):424-5.32. Vasen H.F., Watson P., Mecklin J.P. et al. New clinical criteria for hereditaryVasen H.F., Watson P., Mecklin J.P. et al. New clinical criteria for hereditarynonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.33. Lindor N.M., Rabe K., Petersen G.M. et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;Lindor N.M., Rabe K., Petersen G.M. et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;293:1979-85.:1979-85.34. Kane M.F., Loda M., Gaida G.M. et al. Methylation of the hMLH1 promoterKane M.F., Loda M., Gaida G.M. et al. Methylation of the hMLH1 promotercorrelates with lack of expression of hMLH1 in sporadic colon tumors and mismatchrepair-defective human tumor cell lines. Cancer Res 1997;57:808-11.35. Veigl M.L., Kasturi L., Olechnowicz J. et al. Biallelic inactivation of hMLH1Veigl M.L., Kasturi L., Olechnowicz J. et al. Biallelic inactivation of hMLH1by epigenetic gene silencing, a novel mechanism causing human MSI cancers.Proc Natl Acad Sci U S A 1998; 95(15):8698-702.36. Wang L., Cunningham J.M., Winters J.L. et al. BRAF mutations in colon cancer areWang L., Cunningham J.M., Winters J.L. et al. BRAF mutations in colon cancer arenot likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:520912.37. Sinicrope F.A., Rego R.L., Halling K.C. et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006;Sinicrope F.A., Rego R.L., Halling K.C. et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006;131:729-37.:729-37.38. Roth A.D., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stageRoth A.D., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stageII and III resected colon cancer: results of the translational study on the PETACC-3,EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28(3):466-74.39. Kakar S., Burgart L.J., Thibodeau S.N. et al. Frequency of loss of hMLH1Kakar S., Burgart L.J., Thibodeau S.N. et al. Frequency of loss of hMLH1expression in colorectal carcinoma increases with advancing age. Cancer 2003;97:1421-7.40. Koopman M., Kortman G.A., Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.Koopman M., Kortman G.A., Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.41. Gryfe R., Kim H., Hsieh E.T. et al. Tumour microsatellite instability and clinicalGryfe R., Kim H., Hsieh E.T. et al. Tumour microsatellite instability and clinicaloutcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.42. Ribic C.M., Sargent D.J., Moore M.J. et al. Tumor microsatellite-instability statusRibic C.M., Sargent D.J., Moore M.J. et al. Tumor microsatellite-instability statusas a predictor of benefit from fluorouracilbased adjuvant chemotherapy for coloncancer. N Engl J Med 2003;349(3):247-57.43. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instabilityPopat S., Hubner R., Houlston R.S. Systematic review of microsatellite instabilityand colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.44. Roth A.D., Tejpar S., Yan P. et al. Stage-specific prognostic value of molecularRoth A.D., Tejpar S., Yan P. et al. Stage-specific prognostic value of molecularmarkers in colon cancer: Results of the translational study on the PETACC3 — EORTC 40993-SAKK 60-00 trial. J Clin Oncol (meeting abstract) 2009;27:4002.45. Kerr D., Gray R., Quirke P. et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the gene in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;25(15 Suppl):169s.Kerr D., Gray R., Quirke P. et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the gene in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;25(15 Suppl):169s.46. Sargent D.J., Marsoni S., Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28(20):3219-26.Sargent D.J., Marsoni S., Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28(20):3219-26.47. Carethers J.M., Chauhan D.P., Fink D. et al. Mismatch repair proficiency andCarethers J.M., Chauhan D.P., Fink D. et al. Mismatch repair proficiency andin vitro response to 5-fluorouracil. Gastroenterology 1999;117(1):123-31.48. Fischer F., Baerenfaller K., Jiricny J. 5-fluorouracil is efficiently removed fromFischer F., Baerenfaller K., Jiricny J. 5-fluorouracil is efficiently removed fromDNA by the base excision and mismatch repair systems. Gastroenterology 2007;133(6):1858-68.(6):1858-68.49. Elsaleh H., Iacopetta B. Microsatellite instability is a predictive marker for survivalElsaleh H., Iacopetta B. Microsatellite instability is a predictive marker for survivalbenefit from adjuvant chemotherapy in a population-based series of stage IIIcolorectal carcinoma. Clin Colorectal Cancer 2001;1(2):104-9.50. Jover R., Zapater P., Castells A. et al. The efficacy of adjuvant chemotherapy withJover R., Zapater P., Castells A. et al. The efficacy of adjuvant chemotherapy with5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer2009;45:365-73.;45:365-73.51. Bertagnolli M.M., Niedzwiecki D., Compton C.C. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage IIIBertagnolli M.M., Niedzwiecki D., Compton C.C. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage IIIcolon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27(11):1814-21.52. Carethers J.M., Smith E.J., Behling C.A. et al. Use of 5-flourouracil and survivalCarethers J.M., Smith E.J., Behling C.A. et al. Use of 5-flourouracil and survivalin patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126(2):394-401.53. Barratt P.L., Seymour M.T., Stenning S.P. et al. DNA marcers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360(9343):1381-91.Barratt P.L., Seymour M.T., Stenning S.P. et al. DNA marcers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360(9343):1381-91.54. Storojeva I., Boulay J.L., Heinimann K. et al. Prognostic and predictive relevance ofStorojeva I., Boulay J.L., Heinimann K. et al. Prognostic and predictive relevance ofmicrosatellite instability in colorectal cancer. Oncol Rep 2005;14(1):241-9.55. Des Guetz G., Schischmanoff O., Nicolas P. et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.Des Guetz G., Schischmanoff O., Nicolas P. et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.Eur J Cancer 2009;45(10):1890-6.56. Guastadisegni C., Colafranceschi M., Ottini L. et al. Microsatellite instability as a marker of prognosis and response to therapy: meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46(15):2788-98.Guastadisegni C., Colafranceschi M., Ottini L. et al. Microsatellite instability as a marker of prognosis and response to therapy: meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46(15):2788-98.57. Liang J.T., Huang K.C., Lai H.S. et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil and leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002;101(6):519-25.Liang J.T., Huang K.C., Lai H.S. et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil and leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002;101(6):519-25.58. Kim G.P., Colangelo L.H., Wieand H.S. et al. Prognostic and predictive roles of highdegree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25(7):767-72.Kim G.P., Colangelo L.H., Wieand H.S. et al. Prognostic and predictive roles of highdegree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25(7):767-72.59. Fink D., Zheng H., Nebel S. et al. In vitro and in vivo resistance to cisplatine in cells that have lost DNA mismatch repair. Cancer Res 1997;57(10):1841-5.Fink D., Zheng H., Nebel S. et al. In vitro and in vivo resistance to cisplatine in cells that have lost DNA mismatch repair. Cancer Res 1997;57(10):1841-5.60. Vilar E., Scaltriti M., Balmaсa J. et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicityto irinotecan in human colorectal cancer cell lines. Br J Cancer 2008;99(10):1607-12.Vilar E., Scaltriti M., Balmaсa J. et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicityto irinotecan in human colorectal cancer cell lines. Br J Cancer 2008;99(10):1607-12.61. Fallik D., Borrini F., Boige V. et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patient with advanced colorectal cancer. Cancer Res 2003;63(18):5738-44.Fallik D., Borrini F., Boige V. et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patient with advanced colorectal cancer. Cancer Res 2003;63(18):5738-44.62. Mishima M., Samimi G., Kondo A. et al. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002; 38(10):1405-12.Mishima M., Samimi G., Kondo A. et al. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002; 38(10):1405-12.63. Kim S.T., Lee J., Park S.H. et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66:659-67.Kim S.T., Lee J., Park S.H. et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66:659-67.64. Zaanan A., Cuilliere-Dartigues P., Guilloux A. et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21(4):772-80.Zaanan A., Cuilliere-Dartigues P., Guilloux A. et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21(4):772-80.65. Jacob S., Aguado M., Fallik D. et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61(17):6555-62.Jacob S., Aguado M., Fallik D. et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61(17):6555-62.66. Prolla T.A. DNA mismatch repair and cancer. Curr Opin Cell Biol 1998;10(3): 311-6.Prolla T.A. DNA mismatch repair and cancer. Curr Opin Cell Biol 1998;10(3): 311-6.67. Fedier A., Schwarz V.A., Walt H. et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;93(4):571-6.Fedier A., Schwarz V.A., Walt H. et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;93(4):571-6.68. Kim J., Hong Y., Lee J. et al. Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer. ASCO Annual Meeting 2010, Abstract 3579.Kim J., Hong Y., Lee J. et al. Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer. ASCO Annual Meeting 2010, Abstract 3579.